Literature DB >> 23223675

The impact of cardiovascular comorbidities on the outcome of surgery for non-small-cell lung cancer.

Tomoyoshi Takenaka1, Masakazu Katsura, Yasunori Shikada, Syuichi Tsukamoto, Sadanori Takeo.   

Abstract

OBJECTIVE: The presence of cardiovascular comorbidity in non-small-cell lung cancer (NSCLC) patients increases with age. Therefore, the influence of cardiovascular comorbidity in NSCLC patients on their short- or long-term prognosis remains controversial. This study evaluated the possible risk factors related to the short-term and long-term survivals in NSCLC patients with cardiovascular comorbidity.
METHODS: One thousand one hundred and sixty-two consecutive patients with NSCLC who had undergone a surgical resection between 1984 and 2010 were enrolled in this study. A total of 360 (31%) patients with cardiovascular comorbidities were analysed to identify the risk factors for postoperative complications and prognostic factors.
RESULTS: The patients with cardiovascular comorbidity included 301 with hypertension, 28 with coronary artery disease, 35 with peripheral vascular disease, 23 with arrhythmia and 11 with abdominal aortic aneurysm. Eighty-three patients exhibited more than one type of comorbidity. The postoperative cardiovascular morbidity rates were 3.6% in the cardiovascular comorbidity patients and 3.3% among patients without cardiovascular comorbidity (P = 0.73). No correlation was observed between preoperative cardiovascular comorbidity and postoperative pulmonary complications (P = 0.52). The operative mortality rates were 1.0% for the cardiovascular comorbidity patients and 0.8% for the other patients (P = 0.51). No difference in the postoperative outcomes was observed between the patients with and without cardiovascular comorbidity. The 5-year survival rates were 62.5% in comparison with 65.4% among patients without cardiovascular comorbidity (P = 0.48).
CONCLUSIONS: Patients with cardiovascular comorbidity were not found to be at increased risk of mortality and morbidity following surgery for NSCLC. In addition, cardiovascular comorbidity did not influence the long-term outcomes of patients after a pulmonary resection for NSCLC.

Entities:  

Mesh:

Year:  2012        PMID: 23223675      PMCID: PMC3568808          DOI: 10.1093/icvts/ivs489

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  17 in total

1.  Surgical treatment of lung cancer: predicting postoperative morbidity in the elderly population.

Authors:  Natasha M Rueth; Helen M Parsons; Elizabeth B Habermann; Shawn S Groth; Beth A Virnig; Todd M Tuttle; Rafael S Andrade; Michael A Maddaus; Jonathan D'Cunha
Journal:  J Thorac Cardiovasc Surg       Date:  2012-02-15       Impact factor: 5.209

2.  Comorbidities and Charlson score in resected stage I nonsmall cell lung cancer.

Authors:  D Moro-Sibilot; A Aubert; S Diab; S Lantuejoul; P Fourneret; E Brambilla; C Brambilla; P Y Brichon
Journal:  Eur Respir J       Date:  2005-09       Impact factor: 16.671

3.  Perioperative mortality and major cardio-pulmonary complications after lung surgery for non-small cell carcinoma.

Authors:  M Licker; M de Perrot; L Höhn; J M Tschopp; J Robert; J G Frey; A Schweizer; A Spiliopoulos
Journal:  Eur J Cardiothorac Surg       Date:  1999-03       Impact factor: 4.191

4.  Outcome after lung cancer surgery. Factors predicting early mortality and major morbidity.

Authors:  G Myrdal; G Gustafsson; M Lambe; L G Hörte; E Ståhle
Journal:  Eur J Cardiothorac Surg       Date:  2001-10       Impact factor: 4.191

5.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

6.  Risk factors for the development of postoperative complications after bronchial sleeve resection for malignancy: a univariate and multivariate analysis.

Authors:  Peter H Hollaus; Gerold Wilfing; Peter N Wurnig; Nestor S Pridun
Journal:  Ann Thorac Surg       Date:  2003-03       Impact factor: 4.330

7.  The impact of cardiovascular comorbidity on the outcome of surgery for stage I and II non-small-cell lung cancer.

Authors:  Vincenzo Ambrogi; Eugenio Pompeo; Stefano Elia; Giuseppe Raimondo Pistolese; Tommaso Claudio Mineo
Journal:  Eur J Cardiothorac Surg       Date:  2003-05       Impact factor: 4.191

8.  Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer.

Authors:  M L G Janssen-Heijnen; S Smulders; V E P P Lemmens; F W J M Smeenk; H J A A van Geffen; J W W Coebergh
Journal:  Thorax       Date:  2004-07       Impact factor: 9.139

9.  Data from The Society of Thoracic Surgeons General Thoracic Surgery database: the surgical management of primary lung tumors.

Authors:  Daniel J Boffa; Mark S Allen; Joshua D Grab; Henning A Gaissert; David H Harpole; Cameron D Wright
Journal:  J Thorac Cardiovasc Surg       Date:  2007-12-21       Impact factor: 5.209

10.  Risk factors for early mortality and major complications following pneumonectomy for non-small cell carcinoma of the lung.

Authors:  Marc Licker; Anastase Spiliopoulos; Jean-Georges Frey; John Robert; Laurent Höhn; Marc de Perrot; Jean-Marie Tschopp
Journal:  Chest       Date:  2002-06       Impact factor: 9.410

View more
  9 in total

1.  eComment. Video-assisted thoracoscopic surgery may be an alternative diagnosis and treatment option.

Authors:  Mustafa Cakar; Sevket Balta; Sait Demirkol; Hakan Sarlak
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-03

2.  Decrease in performance status after lobectomy mean poor prognosis in elderly lung cancer patients.

Authors:  Yo Kawaguchi; Jun Hanaoka; Yasuhiko Oshio; Masayuki Hashimoto; Tomoyuki Igarashi; Yoko Kataoka; Ryosuke Kaku; Yuki Namura; Akira Akazawa
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

3.  Outcomes of lung cancer surgery in patients with coronary artery disease: a decade of experience at a single institution.

Authors:  Ryu Kanzaki; Masayoshi Inoue; Masato Minami; Yasushi Shintani; Soichiro Funaki; Tomohiro Kawamura; Meinoshin Okumura
Journal:  Surg Today       Date:  2016-05-19       Impact factor: 2.549

4.  Incidence and predictors of 30-day cardiovascular complications in patients undergoing head and neck cancer surgery.

Authors:  Eeva Haapio; T Kiviniemi; H Irjala; P Koivunen; J K E Airaksinen; I Kinnunen
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-07-04       Impact factor: 2.503

5.  Improved long-term survival following pulmonary resections for non-small cell lung cancer: results of a nationwide study from Iceland.

Authors:  Hannes Halldorsson; Andri Wilberg Orrason; Gudrun Nina Oskarsdottir; Astridur Petursdottir; Bjorn Mar Fridriksson; Magnus Karl Magnusson; Steinn Jonsson; Tomas Gudbjartsson
Journal:  Ann Transl Med       Date:  2019-03

6.  [Analysis of Postoperative Complications and Risk Factors of Patients with Lung Cancer through Clavien-Dindo Classification].

Authors:  Pengfei Li; Yutian Lai; Kun Zhou; Guowei Che
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2017-04-20

Review 7.  Are cardiovascular comorbidities always associated with a worse prognosis in patients with lung cancer?

Authors:  Sabina Mędrek; Sebastian Szmit
Journal:  Front Cardiovasc Med       Date:  2022-09-23

8.  Surgery for non-small cell lung cancer in patients with a history of cardiovascular surgery.

Authors:  Hideyuki Maeda; Masato Kanzaki; Kei Sakamoto; Tamami Isaka; Kenji Yamazaki; Takamasa Onuki
Journal:  Surg Today       Date:  2016-07-21       Impact factor: 2.549

9.  Impact of previous percutaneous coronary intervention on cardiovascular outcomes and mortality after lung cancer surgery: A nationwide study in Korea.

Authors:  Dong Woog Yoon; Dong Wook Shin; Jong Ho Cho; Jong-Hwan Lee; Jeong Hoon Yang; Kyungdo Han; Sang Hyun Park
Journal:  Thorac Cancer       Date:  2020-07-12       Impact factor: 3.500

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.